Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756387 | PMC |
| http://dx.doi.org/10.1016/j.eururo.2019.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.
J Cell Mol Med
December 2024
Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Cisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin-based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis. Therefore, there is a high clinical need for new therapeutic strategies targeting cisplatin-resistant TGCTs.
View Article and Find Full Text PDFPotential next generation markers of testicular germ cell tumors: miRNA-371a-3p.
Int Urol Nephrol
November 2024
Department of Urology, Honghe Hospital Affiliated to Kunming Medical University(South Yunnan Central Hospital of Yunnan Province), Honghe, 661017, Yunnan Province, China.
Article Synopsis
- - Testicular germ cell tumors (TGCTs) are the most common type of testicular cancer in young to middle-aged men, with a high cure rate of over 95% when diagnosed early; however, traditional serum tumor markers (STMs) have less than 60% sensitivity.
- - miRNA-371a-3p, a microRNA associated with embryonic stem cells, has been found to be specifically expressed in TGCTs and offers superior diagnostic and follow-up capabilities compared to conventional STMs, garnering interest in clinical guidelines.
- - A comprehensive study reviewed 368 research articles on miRNA-371a-3p, culminating in 67 relevant studies that confirm its effectiveness as a sensitive blood
A Unique Case of Bilateral Testicular Tumours: Nonseminomatous Germ Cell Tumour and Contralateral Spermatocytic Tumour 27 Years Apart.
Urol Int
November 2024
Department of Urology, Asklepios Klinik Altona, Hamburg, Germany.
Introduction: Bilateral testicular tumours occur in 3-5% of all cases with testicular neoplasms. In the majority of cases, histology of the two new growths is identical. The time interval between the two neoplastic events rarely exceeds 10 years.
View Article and Find Full Text PDFPerioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.
Eur Urol Open Sci
October 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: MicroRNAs (miRNAs) show promise as blood-based tumor markers for germ cell tumors (GCTs), with miRNA-371-3p being the most studied. The marginal benefit of including other candidate miRNAs to aid with the management of testicular GCTs remains unclear.
Objective: To assess the performance of our combined miRNA assay (371a-3p and 372-3p) in patients with clinically localized testicular masses.
[Testicular Germ Cell Tumours - features and prospects of the novel tumour marker microRNA-371a-3p (M371 test): a narrative review].
Aktuelle Urol
December 2024
Universität Bremen, Institut für Tumordiagnostik, Bremen, Germany.
Testicular germ cell tumours (GCTs) represent a paradigm for the usefulness of serum tumour markers in clinical management of diseases. However, the tumour markers currently in use, beta human chorionic gonadotropin (bHCG), alpha fetoprotein (AFP) and lactate dehydrogenase (LDH) are expressed in less than 50% of GCT cases. In 2011, microRNA-371a-3p (currently named M371) was suggested as a novel marker for the first time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!